Abridge Raises $300 million Series E
Abridge raised $300M in Series E financing led by Various. Participating investors included Spark Capital, GV, Various. The stated use of funds is National rollout to health systems across US.
What it does
Abridge operates in Healthcare & Life Sciences and describes its product through its website and announcement materials. The platform addresses workflows that remain fragmented across legacy tools, manual processes, or incumbent providers. Its mechanism is grounded in the company's disclosed product language rather than inferred claims.
Traction
90% of physicians say Abridge reduced burnout. Additional customer, revenue, and growth metrics were not disclosed in the available source bundle.
Trend impact
Abridge's latest round puts more pressure on legacy providers and manual workflows in Healthcare & Life Sciences. The timing matters because fresh capital is flowing to companies that can convert operational complexity into software-led execution. Competitors now have to respond with clearer product depth, pricing, or distribution.
Funding history
- June 1, 2025 · Series E · $300 million · Spark Capital, GV, Various
- Recent · Series E · $300 million · undisclosed investors
- February 1, 2025 · Series D · $250 million · Elad Gil
- Recent · Series D · $250 million · undisclosed investors
- February 1, 2024 · Series C · $150 million · Spark Capital
- May 1, 2023 · Series C · $150 million · Spark Capital
Products & services
- Healthcare & Life Sciences workflow monitoring tied to the funding announcement
- Customer-facing product described on the company website
- Operational tooling for healthcare & life sciences teams
- Data capture and reporting across core business processes
- Team expansion support funded by the latest round